癌症治療基因組學市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、技術、應用、最終用戶、地區和競爭細分，2020-2030 年

2024 年全球癌症治療基因體學市場價值為 157.3 億美元，預計到 2030 年將達到 402.2 億美元，複合年成長率為 16.91%。隨著精準醫療的日益普及和基因組技術的進步，全球癌症治療基因組學市場正在經歷顯著成長。下一代定序 (NGS)、液體活體組織切片和人工智慧在癌症診斷和治療中的整合改變了腫瘤治療。癌症發病率的上升和個人化治療需求的不斷成長加速了對基於基因組的解決方案的需求。製藥公司、研究機構和診斷公司正在合作開發生物標記驅動的癌症療法，以提高治療效果和患者治療效果。基因組資料分析工具和生物資訊學平台的不斷發展進一步支持了市場的擴張，使基因組學成為現代癌症治療的重要組成部分。

主要市場促進因素

基因組定序的進展

主要市場挑戰

成本和可訪問性

主要市場趨勢

液體活體組織切片和早期檢測

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球癌症治療基因體學市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按產品（儀器、耗材、服務）
  • 依技術分類（基因組定序、PCR、微陣列、核酸萃取和純化、其他）
  • 按應用（診斷、個人化醫療、藥物研發、研究）
  • 按最終使用者（醫院、研究機構和學術機構、其他）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第 6 章：北美癌症治療基因體學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 7 章：歐洲癌症治療基因體學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太地區癌症治療基因體學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 韓國
  • 日本
  • 澳洲

第 9 章：南美洲癌症治療基因體學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲癌症治療基因組學市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Illumina Inc
• Agilent Technologies, Inc.
• Roche Diagnostics
• Cancer Genetics, Inc.
• Bio-Rad Laboratories Inc
• Sigma-Aldrich Corp
• QIAGEN NV
• GE Healthcare Inc
• Life Technologies Corp
• Quest Diagnostics Inc

第 15 章：策略建議

第16章調查會社について,免責事項

Global Genomics in Cancer Care Market was valued at USD 15.73 Billion in 2024 and is expected to reach USD 40.22 Billion in the forecast period with a CAGR of 16.91% through 2030. The Global Genomics in Cancer Care Market is experiencing significant growth due to the increasing adoption of precision medicine and advancements in genomic technologies. The integration of next-generation sequencing (NGS), liquid biopsy, and artificial intelligence in cancer diagnostics and treatment has transformed oncology care. Rising cancer prevalence and the growing need for personalized therapies have accelerated the demand for genomic-based solutions. Pharmaceutical companies, research institutions, and diagnostic firms are collaborating to develop biomarker-driven cancer therapies, enhancing treatment efficacy and patient outcomes. The continuous evolution of genomic data analysis tools and bioinformatics platforms further supports the market's expansion, making genomics an essential component of modern cancer care.

Key Market Drivers

Advancements in Genomic Sequencing

In the ever-evolving landscape of cancer care, genomic sequencing has emerged as a potent tool, significantly shaping the Global Genomics in Cancer Care Market. Advancements in genomic sequencing, particularly Next-Generation Sequencing (NGS), have enabled comprehensive molecular profiling of cancer. This allows researchers and healthcare providers to analyze a patient's entire genome to identify mutations, alterations, and genetic markers associated with cancer, facilitating more accurate diagnoses and tailored treatment strategies.

The Cancer Genome Atlas (TCGA), a landmark program by the National Cancer Institute (NCI), has molecularly characterized over 20,000 primary cancer and matched normal samples across 33 cancer types. This extensive dataset, comprising more than two petabytes of genomic data, is publicly available and aids the cancer research community in improving prevention, diagnosis, and treatment strategies.

Genomic sequencing allows for the identification of specific genetic mutations driving a patient's cancer, which is invaluable in developing targeted therapies. Pharmaceutical companies leverage genomic insights to create drugs that precisely target the genetic abnormalities responsible for cancer growth, increasing treatment effectiveness and reducing side effects.

Personalized medicine, based on genomic sequencing, has revolutionized cancer care. By analyzing a patient's genetic makeup, oncologists can tailor treatment plans to the individual, optimizing therapy selection and dosage. This approach not only improves patient outcomes but also enhances the overall quality of life during treatment.

Genomic sequencing also plays a crucial role in early detection and prevention. Genetic testing can identify individuals with a higher risk of developing certain cancers, enabling early interventions and proactive health management. Additionally, screening for genetic markers associated with cancer allows for earlier diagnosis and intervention, increasing the chances of successful treatment.

The wealth of data generated through genomic sequencing is a goldmine for researchers and healthcare providers. Advanced data analytics and bioinformatics tools are employed to interpret and extract meaningful insights from genomic data, leading to more informed clinical decisions and supporting ongoing research into new cancer therapies and diagnostic tools.

Advancements in genomic sequencing have driven down the cost of sequencing, making it more accessible for patients and healthcare providers. As sequencing becomes more affordable, its adoption in clinical settings becomes more widespread, further fueling market growth.

In summary, the integration of genomic sequencing into cancer care has transformed the approach to diagnosis, treatment, and prevention, driving significant advancements in the Global Genomics in Cancer Care Market.

Key Market Challenges

Cost and Accessibility

The high cost of genomic technologies and limited accessibility to advanced cancer care remain significant challenges in the Global Genomics in Cancer Care Market. Next-generation sequencing (NGS), whole genome sequencing, and other genomic profiling techniques require expensive instruments, reagents, and bioinformatics infrastructure, making them unaffordable for many healthcare providers and patients. The cost burden is further exacerbated by the need for specialized expertise to interpret complex genomic data, increasing operational expenses for diagnostic laboratories and hospitals. Many low- and middle-income countries struggle to integrate genomic-based cancer diagnostics into their healthcare systems due to budget constraints and the lack of reimbursement policies for these advanced tests.

Limited accessibility to genomic cancer care is another critical issue, particularly in remote and underserved regions. Many healthcare facilities lack the necessary infrastructure to conduct in-house genomic testing, leading to delays in diagnosis and treatment initiation. Patients in such areas often need to travel long distances to access specialized centers, increasing financial and logistical burdens. The disparity in access to genomic testing is also evident within high-income countries, where only major medical centers offer comprehensive genomic profiling, while smaller hospitals and clinics face resource limitations. The absence of standardized regulations and inconsistent reimbursement policies across different regions further hinder the widespread adoption of genomic technologies in oncology.

Key Market Trends

Liquid Biopsies and Early Detection

The Global Genomics in Cancer Care Market is experiencing a significant shift toward liquid biopsies and early detection, driven by advancements in next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis. Liquid biopsy is emerging as a revolutionary tool for non-invasive cancer diagnostics, enabling real-time monitoring of tumor progression and treatment response. Traditional tissue biopsies are often invasive, time-consuming, and limited in capturing tumor heterogeneity. Liquid biopsies, on the other hand, provide a comprehensive genomic profile by detecting genetic alterations in circulating biomarkers such as ctDNA, circulating tumor cells (CTCs), and extracellular vesicles in blood samples. The increasing adoption of this technology is improving early cancer detection rates, enhancing treatment personalization, and reducing the need for repeated invasive procedures.

Key Market Players

• Illumina Inc
• Agilent Technologies, Inc.
• Roche Diagnostics
• Cancer Genetics, Inc.
• Bio-Rad Laboratories Inc
• Sigma-Aldrich Corp
• QIAGEN NV
• GE Healthcare Inc
• Life Technologies Corp
• Quest Diagnostics Inc

Report Scope:

In this report, the Global Genomics in Cancer Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomics in Cancer Care Market, By Product:

• Instruments
• Consumables
• Services

Genomics in Cancer Care Market, By Technology:

• Genome Sequencing
• PCR
• Microarray
• Nucleic Acid Extraction and Purification
• Others

Genomics in Cancer Care Market, By Application:

• Diagnostics
• Personalized Medicine
• Drug Discovery & Development
• Research

Genomics in Cancer Care Market, By End User:

• Hospitals
• Research Institutes & Academic Institutes
• Others

Genomics in Cancer Care Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genomics in Cancer Care Market.

Available Customizations:

Global Genomics in Cancer Care market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Genomics in Cancer Care Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Consumables, Services)
  • 5.2.2. By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification, Others)
  • 5.2.3. By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research)
  • 5.2.4. By End User (Hospitals, Research Institutes & Academic Institutes, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Genomics in Cancer Care Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genomics in Cancer Care Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Genomics in Cancer Care Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Genomics in Cancer Care Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Genomics in Cancer Care Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Genomics in Cancer Care Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Genomics in Cancer Care Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Genomics in Cancer Care Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Genomics in Cancer Care Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Genomics in Cancer Care Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Genomics in Cancer Care Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Genomics in Cancer Care Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Genomics in Cancer Care Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Genomics in Cancer Care Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Genomics in Cancer Care Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Genomics in Cancer Care Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Genomics in Cancer Care Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Genomics in Cancer Care Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Genomics in Cancer Care Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Genomics in Cancer Care Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Genomics in Cancer Care Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Genomics in Cancer Care Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Genomics in Cancer Care Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Genomics in Cancer Care Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Illumina Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Agilent Technologies, Inc.
• 14.3. Roche Diagnostics
• 14.4. Cancer Genetics, Inc.
• 14.5. Bio-Rad Laboratories Inc
• 14.6. Sigma-Aldrich Corp
• 14.7. QIAGEN NV
• 14.8. GE Healthcare Inc
• 14.9. Life Technologies Corp
• 14.10. Quest Diagnostics Inc

15. Strategic Recommendations

16. About Us & Disclaimer